Validation of the CPS + EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Jad M. Abdelsattar, Zahraa Al-Hilli, Tanya L. Hoskin, Courtney N. Heins, Judy C Boughey

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: CPS + EG staging, which incorporates estrogen receptor (ER) status and tumor grade with pretreatment clinical stage (CS) and post-treatment pathologic stage (PS), has been reported to have better correlation with outcome than classic TNM staging for patients treated with neoadjuvant chemotherapy (NAC). Our goal was to evaluate the performance of CPS + EG staging system in an external cohort treated with NAC. Methods: We reviewed patients with stages I–IIIC breast cancer treated with NAC and surgery at our institution between 1988 and 2014. ER status, Nottingham grade, treatment, American Joint Committee on Cancer (AJCC) CS before NAC and PS after NAC, and follow-up data were collected. The discrimination of CPS + EG and pathologic AJCC stage were assessed using area under the curve (AUC) for survival data. Results: A total of 769 patients were analyzed with a median follow-up of 2.6 (range 0.0–19.4) years; 103 patients died of breast cancer. Overall, the 5-year breast cancer cause-specific survival was 81.5 % [95 % confidence interval (CI) 77.6–85.5]. The 5-year, cause-specific survival by CPS + EG score was 93.8 % score 0, 89.9 % score 1, 90.7 % score 2, 84.8 % score 3, 67.7 % score 4, and 43.4 % score 5/6. CPS + EG score was significantly associated with cause-specific survival (p < 0.001) with an AUC of 0.69 (95 % CI 0.62–0.77) at 5 years. This was higher than the AUC of 0.63 (95 % CI 0.56–0.70) for AJCC PS (p = 0.10). Conclusions: This study validates the CPS + EG staging system using Nottingham grade in an external cohort. Addition of tumor biology and treatment response shows promise in improving survival estimates for patients treated with NAC.

Original languageEnglish (US)
Pages (from-to)3206-3211
Number of pages6
JournalAnnals of Surgical Oncology
Volume23
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Breast Neoplasms
Drug Therapy
Survival
Area Under Curve
Confidence Intervals
Neoplasms
Estrogen Receptors
Neoplasm Staging
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Validation of the CPS + EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. / Abdelsattar, Jad M.; Al-Hilli, Zahraa; Hoskin, Tanya L.; Heins, Courtney N.; Boughey, Judy C.

In: Annals of Surgical Oncology, Vol. 23, No. 10, 01.10.2016, p. 3206-3211.

Research output: Contribution to journalArticle

Abdelsattar, Jad M. ; Al-Hilli, Zahraa ; Hoskin, Tanya L. ; Heins, Courtney N. ; Boughey, Judy C. / Validation of the CPS + EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. In: Annals of Surgical Oncology. 2016 ; Vol. 23, No. 10. pp. 3206-3211.
@article{284823c9c1bf4ca2ae14088b7f0017c5,
title = "Validation of the CPS + EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy",
abstract = "Background: CPS + EG staging, which incorporates estrogen receptor (ER) status and tumor grade with pretreatment clinical stage (CS) and post-treatment pathologic stage (PS), has been reported to have better correlation with outcome than classic TNM staging for patients treated with neoadjuvant chemotherapy (NAC). Our goal was to evaluate the performance of CPS + EG staging system in an external cohort treated with NAC. Methods: We reviewed patients with stages I–IIIC breast cancer treated with NAC and surgery at our institution between 1988 and 2014. ER status, Nottingham grade, treatment, American Joint Committee on Cancer (AJCC) CS before NAC and PS after NAC, and follow-up data were collected. The discrimination of CPS + EG and pathologic AJCC stage were assessed using area under the curve (AUC) for survival data. Results: A total of 769 patients were analyzed with a median follow-up of 2.6 (range 0.0–19.4) years; 103 patients died of breast cancer. Overall, the 5-year breast cancer cause-specific survival was 81.5 {\%} [95 {\%} confidence interval (CI) 77.6–85.5]. The 5-year, cause-specific survival by CPS + EG score was 93.8 {\%} score 0, 89.9 {\%} score 1, 90.7 {\%} score 2, 84.8 {\%} score 3, 67.7 {\%} score 4, and 43.4 {\%} score 5/6. CPS + EG score was significantly associated with cause-specific survival (p < 0.001) with an AUC of 0.69 (95 {\%} CI 0.62–0.77) at 5 years. This was higher than the AUC of 0.63 (95 {\%} CI 0.56–0.70) for AJCC PS (p = 0.10). Conclusions: This study validates the CPS + EG staging system using Nottingham grade in an external cohort. Addition of tumor biology and treatment response shows promise in improving survival estimates for patients treated with NAC.",
author = "Abdelsattar, {Jad M.} and Zahraa Al-Hilli and Hoskin, {Tanya L.} and Heins, {Courtney N.} and Boughey, {Judy C}",
year = "2016",
month = "10",
day = "1",
doi = "10.1245/s10434-016-5324-y",
language = "English (US)",
volume = "23",
pages = "3206--3211",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Validation of the CPS + EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

AU - Abdelsattar, Jad M.

AU - Al-Hilli, Zahraa

AU - Hoskin, Tanya L.

AU - Heins, Courtney N.

AU - Boughey, Judy C

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background: CPS + EG staging, which incorporates estrogen receptor (ER) status and tumor grade with pretreatment clinical stage (CS) and post-treatment pathologic stage (PS), has been reported to have better correlation with outcome than classic TNM staging for patients treated with neoadjuvant chemotherapy (NAC). Our goal was to evaluate the performance of CPS + EG staging system in an external cohort treated with NAC. Methods: We reviewed patients with stages I–IIIC breast cancer treated with NAC and surgery at our institution between 1988 and 2014. ER status, Nottingham grade, treatment, American Joint Committee on Cancer (AJCC) CS before NAC and PS after NAC, and follow-up data were collected. The discrimination of CPS + EG and pathologic AJCC stage were assessed using area under the curve (AUC) for survival data. Results: A total of 769 patients were analyzed with a median follow-up of 2.6 (range 0.0–19.4) years; 103 patients died of breast cancer. Overall, the 5-year breast cancer cause-specific survival was 81.5 % [95 % confidence interval (CI) 77.6–85.5]. The 5-year, cause-specific survival by CPS + EG score was 93.8 % score 0, 89.9 % score 1, 90.7 % score 2, 84.8 % score 3, 67.7 % score 4, and 43.4 % score 5/6. CPS + EG score was significantly associated with cause-specific survival (p < 0.001) with an AUC of 0.69 (95 % CI 0.62–0.77) at 5 years. This was higher than the AUC of 0.63 (95 % CI 0.56–0.70) for AJCC PS (p = 0.10). Conclusions: This study validates the CPS + EG staging system using Nottingham grade in an external cohort. Addition of tumor biology and treatment response shows promise in improving survival estimates for patients treated with NAC.

AB - Background: CPS + EG staging, which incorporates estrogen receptor (ER) status and tumor grade with pretreatment clinical stage (CS) and post-treatment pathologic stage (PS), has been reported to have better correlation with outcome than classic TNM staging for patients treated with neoadjuvant chemotherapy (NAC). Our goal was to evaluate the performance of CPS + EG staging system in an external cohort treated with NAC. Methods: We reviewed patients with stages I–IIIC breast cancer treated with NAC and surgery at our institution between 1988 and 2014. ER status, Nottingham grade, treatment, American Joint Committee on Cancer (AJCC) CS before NAC and PS after NAC, and follow-up data were collected. The discrimination of CPS + EG and pathologic AJCC stage were assessed using area under the curve (AUC) for survival data. Results: A total of 769 patients were analyzed with a median follow-up of 2.6 (range 0.0–19.4) years; 103 patients died of breast cancer. Overall, the 5-year breast cancer cause-specific survival was 81.5 % [95 % confidence interval (CI) 77.6–85.5]. The 5-year, cause-specific survival by CPS + EG score was 93.8 % score 0, 89.9 % score 1, 90.7 % score 2, 84.8 % score 3, 67.7 % score 4, and 43.4 % score 5/6. CPS + EG score was significantly associated with cause-specific survival (p < 0.001) with an AUC of 0.69 (95 % CI 0.62–0.77) at 5 years. This was higher than the AUC of 0.63 (95 % CI 0.56–0.70) for AJCC PS (p = 0.10). Conclusions: This study validates the CPS + EG staging system using Nottingham grade in an external cohort. Addition of tumor biology and treatment response shows promise in improving survival estimates for patients treated with NAC.

UR - http://www.scopus.com/inward/record.url?scp=84975222122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975222122&partnerID=8YFLogxK

U2 - 10.1245/s10434-016-5324-y

DO - 10.1245/s10434-016-5324-y

M3 - Article

VL - 23

SP - 3206

EP - 3211

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -